anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: This review examines the role of different viral infections in epileptogenesis, with a focus on Herpesviruses such as Human Herpesvirus 6 (HHV-6) and Epstein Barr Virus (EBV), Flaviviruses, Picornaviruses, Human Immunodeficiency Virus (HIV), Influenzavirus and Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2).
RECENT FINDINGS: A growing literature on animal models, such as the paradigmatic Theiler's murine encephalomyelitis virus (TMEV) model, and clinical investigations in patients with epilepsy have started to elucidate cellular mechanisms implicated in seizure initiation and development of epilepsy following viral infections. A central role of neuroinflammation has emerged, with evidence of activation of the innate and adaptive immunity, dysregulation of microglial and astrocytic activity and production of multiple cytokines and other inflammatory mediators. Several chronic downstream effects result in increased blood-brain barrier permeability, direct neuronal damage, and modifications of ion channels ultimately leading to altered neuronal excitability and seizure generation. Key findings underscore the complex interplay between initial viral infection, neuroinflammation, and later development of epilepsy. Further research is needed to elucidate these mechanisms and develop targeted interventions.
Surgical excision is the gold standard for the treatment for localized kidney cancer. An organ-preserving procedure should be carried out whenever possible in order to maintain kidney function. Partial nephrectomy can be performed through the conventional open technique as well as through a robotic-assisted approach. Although both methods belong to the standard care, there is still no published data from randomized controlled trials in the scientific literature comparing them. The ROBOCOP-trial is designed as a single-center comparison of the two surgical approaches in preparation for a phase III study. 50 patients are to be included in the trial within a period of 15 months. The primary endpoint is feasibility of patient recruitment. In addition, potential primary outcomes for a confirmative trial such as perioperative complications, quality of life, inflammatory response, survival and ergonomic aspects for the operating surgeons will be investigated.
The present invention relates to peripheral blood-derived iNKT cells, methods for their preparation and their use in leukemia, which is acute T-lymphoblastic leukemia. The method for preparing the external Zhou Xieyuan iNKT cell comprises the following steps: isolation of mononuclear cells from peripheral blood, and magnetic bead separation of mononuclear cells to obtain CD34  +  Cells, CD34 obtained  +  The cells and the mesenchymal stem cells are co-cultured in a complete medium, the cells are induced and differentiated to obtain iNKT cells, and the iNKT cells are amplified and cultured by using an NK supplementing medium to obtain a large number of iNKT cells. The invention also relates to an iNKT cell derived from peripheral blood, which is prepared by the method of the invention. Also relates to a method for the inventionComplete medium of (a) and NK supplementation medium. The method of the present invention for preparing iNKT cells using peripheral blood presents advantages such as high expansion ratio. The iNKT cells exhibit excellent antitumor activity.
As spasmolytic agents (see Group VI) are employed the esters of benzilic acid forming the subject of Specification 740,959, and also the methanol, ethanol, propanol-1 and -2, butanol-1, pentanol-1, 2-methylbutanol-4 and benzyl alcohol esters, the properties of which are given in a table.ALSO:Therapeutic preparations for internal application (as spasmolytics) comprise an ester, free from basic nitrogen, of benzilic acid with thymol or an alcohol containing not more than 12 carbon atoms in the molecule, together with a carrier suitable for therapeutic use for internal application.  For oral administration, the esters, as such or adsorbed or a solid adsorbent, may be worked up into wafer-seals, or, with fillers if necessary, into tablets, which may be sugar coated, or capsules may be filled with a solution, emulsion or suspension of the ester, e.g. in a fatty oil, or a suspension or emulsion of the ester in water may be taken as a draught.  For injection the esters may be dissolved in organic solvents (including fatty oils to which a wax may be added for forming a depot therapeutic material), or in water with the aid of solubilizing agents, or may be dispersed in water with the aid of a surface-active agent. They may also be formed into suppositories with a fatty basis.  In examples: (1) the 2-methylbutanol-1 ester is adsorbed on a mixture of lactose and oxidized starch, and the product, with the addition of talcum and magnesium stearate, is pressed into tablets, which in (2) are coated with a mixture of sugar, talcum venetum and gelatin; (3) gelatin capsules are filled with a solution of the heptanol-1 ester in arachis oil; (4) a wafer-seal is filled with a mixture of lactose and oxidized starch on which the benzyl ester is adsorbed; (5) a draught is prepared by dispersing the 2-ethyl-hexanol ester in an aqueous solution of sugar and a vegetable gum or carboxymethylcellulose; (6) ampoules are filled with a solution of the 2-methylpropanol-1 ester in 1 : 2-propylene glycol or a mixture thereof with benzyl alcohol and water, and then sterilized with steam; (7) suppositories are cast from a mixture prepared by stirring the 2-methylbutanol-1 ester into a melt of polyethylene sorbitan monostearate and glyceryl laurate. The spasmolytic properties of the esters with methanol, ethanol, propanol-1 and -2, butanol-1, pentanol-1, -2 and -3, 2-methylbutanol-4, fermentation amyl alcohol, heptanol-3, 2-methylhexanol-1, 2 : 6-dimethylheptanol-4, 3 : 5 : 5-trimethylhexanol-1, 5-ethylnonanol-2, dodecanol-1, 2 : 6 : 8-trimethylnonanol-4, 3 : 3 : 5-trimethylcyclohexanol, l-menthol, borneol and tetrahydrofurfuryl alcohol are also given, and still further alcohols are listed.  Additional carrier materials specified are: adsorbents: bolus alba and colloidal silicic acid; filler for tablets; saccharose; solvents: glycerol, glyceryl diethyl ether, and a mixture of alcohol, glycerol and water; substances increasing the solubility of the esters in water: methane, substituted amides, methylglucamine and polyvinylpyrrolidone; suppository base: cacao butter. Specification 740,959, [Group IV(b)], and U.S.A. Specification 2,399,736 are referred to.
AIM: To assess the effect of obesity phenotype on the incidence of diabetes, considering phenotype as a time-varying exposure.
METHODS: We used community-based cohort data from the Korean Genome and Epidemiology Study, with a 16-year follow-up period. Obesity phenotype was determined using body mass index and metabolic syndrome criteria. The influence of obesity phenotype on the occurrence of diabetes was evaluated using a Cox proportional hazard model and a marginal structural model (MSM).
RESULTS: Obesity phenotypes were defined in 6265 individuals, with diabetes identified in 903 (14.4%) during the follow-up period. Individuals with metabolically healthy obesity (MHO) exhibited a higher risk of diabetes compared to those with metabolically healthy normal weight (MHNW), with a hazard ratio (HR) of 1.48 (95% confidence interval [CI] 1.15-1.90). This association remained significant after applying the MSM (HR 1.49, 95% CI 1.01-2.20). Moreover, various sensitivity analyses consistently demonstrated a higher risk of diabetes in individuals with MHO compared to those with MHNW.
CONCLUSIONS: Even when obesity phenotype was treated as a time-varying exposure, individuals with MHO were still at higher risk for developing diabetes than those with MHNW. Consequently, such individuals should aim to avoid transitioning to a metabolically unfavourable state and strive to reduce their body weight to a normal range.
Inventors have shown that targeting DDR1 and DDR2 collagen receptors by Imatinib resensitizes melanoma tumors to BRAFV600E to targeted therapy and normalizes the fibrotic stromal reaction. These findings provide the rationale to combine Imatinib (or other DDR inhibitors) and MAPK-targeting agents to disrupt the influence of the matrix microenvironment in order to delay or prevent the emergence of therapy-resistant cells. They have shown that inhibition of DDR1 and DDR2 kinase activities by Imatinib suppressed the protection of melanoma cells against Vemurafenib (BRAFi) and Trametinib (MEKi) co-drugging and led to cell cycle arrest and cell death. Similar biochemical cell cycle and apoptotic events were promoted in presence of Nilotinib. They validated this anti- tumor activity of Imatinib combined with Vemurafenib in a pre-clinical xenograft model of melanoma and showed that targeting DDR1/2 signaling delays tumor relapse. Accordingly, the present invention relates to a method for treating melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of : i) an inhibitor of BRAF, ii) an inhibitor of MEK, and iii) an inhibitor of DDR1/2.
OBJECTIVES: I. Determine the objective response rate in patients with metastatic or recurrent thymoma treated with octreotide. II. Determine the duration of remission in these patients. III. Determine the toxicity of the octreotide regimen in this population. IV. Determine the response rate, duration of remission, survival and toxicity of prednisone added to octreotide in patients with stable disease following octreotide alone.

OUTLINE: All patients receive octreotide subcutaneously three times daily for 1 month. After two courses of treatment, patients are assessed for response. Patients experiencing partial or complete response continue octreotide for a maximum of 1 year (12 courses) in the absence of unacceptable toxicity or disease progression. Patients with stable disease after 2 courses of octreotide receive daily oral prednisone in addition to octreotide for an additional 2 courses. These patients are then reevaluated and continue on octreotide plus prednisone for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 1 year, every 4 months for the second year, every 6 months for the next 3 years, and then annually thereafter.

PROJECTED ACCRUAL: There will be 38 patients accrued into this study over approximately 2 years.
PURPOSE:To provide a biological kidney growth promoter capable of activating the kidney reduced in nephrocyter or the function and expecting nephrocyte increase and the improvement of kidney function improvement with excellent safety. CONSTITUTION:The objective kidney growth promoter is derived from a natural material, containing, as the active component, a hybrid containing luteinzing hormone (LH).subunit, preferably a gonadotropic hormone hybrid containing LH alpha- or beta-subunit, showing the above-mentioned pharmacological effects and has excellent safety. In addition, e.g. chorionic gonodotropin(CG) or follicle- stimulating hormone(FSH), especially(CG) can be used as the above-mentioned gonadotropic hormone. LH, CG, FSH, ETC., as the raw materials are obtained from natural materials by extraction method or an artificial production method and the subunits separated therefrom by known method can be used. Further, the above-mentioned hybrid can be prepared therefrom by suitably using a known combination method.
A traditional Chinese medicine preparation for treating rhinitis and a preparation method thereof are prepared from traditional Chinese medicine raw materials which comprise the following raw materials in parts by weight: 18-24 parts of rhizoma polygonati; 28-32 parts of astragalus; 18-24 parts of gecko; 8-14 parts of bletilla striata; 18-22 parts of bulbus fritillariae cirrhosae; 18-22 parts of American ginseng; 26-34 parts of magnolia flower; 26-32 parts of mint; 26-34 parts of radix angelicae; 18-24 parts of asarum; 18-22 parts of common coltsfoot flower; 18-26 parts of purple perilla; 8-12 parts of scutellaria baicalensis; 8-12 parts of honeysuckle; 16-22 parts of honey comb. Tonify lung and kidney, and resolve dampness with aromatics. The rhinitis is quickly cured and is not easy to relapse. The preparation method of the traditional Chinese medicine preparation comprises the steps of cleaning the raw materials, cutting, drying and grinding. Or by respectively concentrating, grinding, extracting aromatic oil, and mixing. The preparation method is simple and easy to implement, various parameters are controllable, and the industrial production is easy to realize.
PURPOSE: A pharmaceutical composition for preventing, treating, or alleviating diseases related to cranial nerves or spinal nerves is provided to treat cerebral infarction using stem cell-conditioned medium powder. CONSTITUTION: A pharmaceutical composition for preventing, treating, or alleviating diseases related to cranial nerves or spinal nerves contains conditioned medium powder. The conditioned medium powder is prepared by culturing stem cells in a serum-free medium and freeze-drying the medium. The diseases related to cranial nerves or spinal nerves includes cerebral infarction, stroke, cerebral inflammatory disease, brain injury, traumatic brain injury, Alzheimer's disease, Parkinson's disease, depression, epilepsy, multiple sclerosis, or mania. The serum-free medium contains growth factors or cytokines. [Reference numerals] (AA) In vivo experiment design; (BB) In vitro experiment design
After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs. The Guided Imagery Programs include: 1.Relaxation and Wellness; 2. Immune System Imagery and 3. Healing Trauma. The study measures are completed upon entry and 21 days post entry into the study and include: PKPCT and 21 days post entry into the study and include: PKPCT and the SF-36v2.
Nogo, MAG, and OMgp are myelin-derived proteins that bind to a neuronal Nogo-66 Receptor (NgR) to limit axonal regeneration after CNS injury. Nogo-A protein may play the most prominent role in vivo, perhaps because its action is mediated both by NgR and by other receptors. Here, we extend our previous analysis of Nogo-A and NgR functional domains. In addition to a NgR-dependent Nogo-66 inhibitory domain and a NgR-independent Amino-Nogo-A specific domain, we identify a third Nogo-A specific domain that binds to NgR with nanomolar affinity. This third domain of 19 amino acids (aa) does not alter cell spreading or axonal outgrowth. Ala-scanning mutagenesis of surface residues in NgR partially distinguishes ligand binding sites for the two Nogo domains and for MAG, OMgp and Lingo-1. Fusion of the two NgR-binding Nogo-A domains creates a ligand with ten-fold enhanced affinity for NgR and converts a NgR antagonist peptide to an agonist. Thus, inhibition of axonal regeneration by NgR occurs after binding a subnanomolar bipartite Nogo-A ligand at a site partly overlapping with that for MAG and OMgp.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median overall survival (OS) of 15-18 months despite standard treatments. Approximately 8% of GBM cases exhibit genomic alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 and FGFR3. Next-generation sequencing techniques have identified various FGFR3 fusions in GBM. This report presents a novel FGFR3 fusion with fatty acid synthase (FASN) in a 41-year-old male diagnosed with GBM. The patient presented with a persistent headache, and imaging revealed a right frontal lobe lesion. Surgical resection and subsequent histopathology confirmed GBM. Initial NGS analysis showed no mutations in the IDH1, IDH2 or H3F3 genes, but revealed a TERT promoter mutation and CDKN2A/2B and PTEN deletions. Postoperative treatment included radiotherapy and temozolomide. Despite initial management, recurrence occurred four months post-diagnosis, confirmed by MRI and histology. A second surgery identified a novel FGFR3-FASN fusion, alongside increased Ki67 expression. The recurrence was managed with regorafenib and bevacizumab, though complications like hand-foot syndrome and radiation necrosis arose. Despite initial improvement, the patient died 15 months after diagnosis. This case underscores the importance of understanding GBM's molecular landscape for effective treatment strategies. The novel FGFR3-FASN fusion suggests potential implications for GBM recurrence and lipid metabolism. Further studies are warranted to explore FGFR3-FASN's role in GBM and its therapeutic targeting.
The invention provides a nucleic acid vector, a nucleic acid medicine, a preparation method and application thereof. Nucleic acid vectors comprising sequences a, b and c, the nucleic acid vectors being selected from the group consisting of DNA, RNA or DNA-RNA hybrid vectors; a. the b and c sequences self-assemble to form a nucleic acid vector, the a, b and c sequences comprising a backbone sequence comprising the core sequence: a1 sequence shown in SEQ ID NO. 1 or 4, a b1 sequence shown in SEQ ID NO. 2 or 5 and a c1 sequence shown in SEQ ID NO. 3 or 6, or any variant sequence of at least one of the a1 sequence, the b1 sequence and the c1 sequence, the variant sequence comprising an insertion, deletion or substitution of at least one base; the DNA-RNA hybrid vector is a vector formed by self-assembly of a combination of the sequence of the DNA vector and the sequence of the RNA vector. The carrier has high delivery efficiency and a more stable delivery system. And the preparation process is simpler and more efficient.
Aims: To assess the potential efficacy and the feasibility of a peer-led brief alcohol intervention aimed to reduce the alcohol consumption in Spanish heavy nursing student drinkers.

Methods: A pilot randomized controlled trial was carried out. Fifty nursing students were randomly assigned either a 50-minute brief motivational enhancement intervention with individual feedback (n=23) or a treatment-as-usual control condition (n=27). Both motivational interviewing and personalized feedback were delivered by undergraduate peer counsellors trained in Brief Alcohol Screening and Intervention for College Students (BASICS). Participants were assessed during their pledge year of university with a one-month follow-up. Primary outcomes for testing efficacy were alcohol use (quantity, heavy-drinking episodes, and peak blood alcohol concentration), and alcohol-related consequences. Quantitative data were analyzed using the U-Mann-Whitney and Wilcoxon test. Content analysis was used for measuring the feasibility of the program.
Objectives: To compare the effects of speed-dependent treadmill training (SDT) on gait and balance performance in patients with sub-acute stroke. Design: Double-blinded randomized controlled trial. Subjects: Twenty-six patients with sub-acute stroke were randomly assigned to SDT (n=13) and control (n=13) groups. Methods: Subjects in the SDT group underwent short interval of walking trials with stepwise increases in the treadmill speed, following the principles of sprint training. Control subjects received gait training on the treadmill with a steady speed (SST). Gait speed, stride length, cadence, and Berg's balance score (BBS) were recorded and analysed before and after the 10 training sessions. Results: Results of two-way repeated measures ANOVA showed significant group x time interactions for gait speed and stride length (p \< 0.05). Within each subject group, there were improvements in all gait parameters and BBS (all p \< 0.001) after the training program. In addition, the SDT group showed significantly larger percentage increases in gait speed (by 72.8%) and stride length (by 29.2%) than the control subjects (p \< 0.02). Conclusions: SDT in patients with sub-acute stroke resulted in larger gains in gait speed and stride length compared with SST. The positive findings provide evidence for clinical practice of SDT in enhancing gait function after stroke.
A single-subject study ABABA design will be used with dependent variables of passive range of motion, functional movement, functional skills performance, engagement, health related quality of life and gait velocity will be recorded repeatedly for the individual participants across time and with systematic manipulation of the independent variable, which is the standing home program intervention. The study will span 28 weeks for the intervention Stage 2, consisting of three baseline phases (A) of four weeks each and two home program intervention phases (B) of eight weeks each that alternate in an ABABA design.
Provided is a nanoparticle associated with a plurality of oleylcysteineamide (OCA) molecules for a variety of therapeutic applications. At least a portion of the OCA molecules may be associated with at least one therapeutic agent or at least one non-active agent. Also provided is a drug delivery agent including at least one nanoparticle associated with a plurality of OCA molecules. At least a portion of the OCA molecules is associated with at least one therapeutic agent or at least one or non-active agent. Also provided is a method of delivering a drug to a subject. The method includes administering the drug delivery agent (associated with the drug) to the subject.